...
首页> 外文期刊>The Journal of Nuclear Medicine >Differentiation of malignant and benign cardiac tumors using 18F-FDG PET/CT
【24h】

Differentiation of malignant and benign cardiac tumors using 18F-FDG PET/CT

机译:使用18F-FDG PET / CT鉴别恶性和良性心脏肿瘤

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

In the diagnostic algorithm of cardiac tumors, the noninvasive determination of malignancy and metastatic spread is of major interest to stratify patients and to select and monitor therapies. In the diagnostic work-up, morphologic imaging modalities such as echocardiography or magnetic resonance tomography offer information on, for example, size, invasiveness, and vascularization. However, preoperative assessment of malignancy may be unsatisfactory. The aim of this study was to evaluate the diagnostic value of 18F-FDG PET and the incremental diagnostic value of an optimized CT score in this clinical scenario. Methods: 18F-FDG PET/CT scans (whole-body imaging with low-dose CT) of 24 consecutive patients with newly diagnosed cardiac tumors were analyzed (11 men, 13 women; mean age ± SD, 59 ± 13 y). The maximum standardized uptake values (SUV max) of the tumors were measured. Patients were divided into 2 groups: benign cardiac tumors (n = 7) and malignant cardiac tumors (n = 17) (cardiac primaries [n = 8] and metastases [n = 9]). SUV max was compared between the 2 groups. Results were compared with contrast-enhanced CT, using standardized criteria of malignancy. Histology served as ground truth. Results: Mean SUV max was 2.8 ± 0.6 in benign cardiac tumors and significantly higher both in malignant primary and in secondary cardiac tumors (8.0 ± 2.1 and 10.8 ± 4.9, P 0.01). Malignancy was determined with a sensitivity of 100% and specificity of 86% (accuracy, 96%), after a cutoff with high sensitivity (SUV max of 3.5) was chosen to avoid false-negatives. Morphologic imaging reached a sensitivity of 82% and a specificity of 86% (accuracy, 83%). Both false-positive and false-negative decisions in morphology could be corrected in all but 1 case using a metabolic threshold with an SUV max of 3.5. In addition, extracardiac tumor manifestations were detected in 4 patients by whole-body 18F-FDG PET/CT. Conclusion: 18F-FDG PET/CT can aid the noninvasive preoperative determination of malignancy and may be helpful in detecting metastases of malignant cardiac tumors.
机译:在心脏肿瘤的诊断算法中,非侵入性确定恶性肿瘤和转移灶是引起患者分层并选择和监测治疗方法的主要兴趣所在。在诊断检查中,诸如超声心动图或磁共振断层扫描等形态学成像方式可提供有关大小,浸润性和血管形成的信息。但是,术前对恶性肿瘤的评估可能并不令人满意。这项研究的目的是评估18F-FDG PET的诊断价值以及在这种临床情况下优化CT评分的递增诊断价值。方法:对24例新诊断出的心脏肿瘤的连续患者(11例男性,13例女性;平均年龄±SD,59±13岁)进行18F-FDG PET / CT扫描(低剂量CT全身成像)。测量了肿瘤的最大标准摄取值(SUV max)。患者分为两组:良性心脏肿瘤(n = 7)和恶性心脏肿瘤(n = 17)(心脏原发[n = 8]和转移灶[n = 9])。比较两组的SUV max。使用标准化的恶性标准,将结果与增强CT进行比较。组织学是事实。结果:良性心脏肿瘤的平均SUV max为2.8±0.6,恶性原发性和继发性心脏肿瘤的SUV max最高(8.0±2.1和10.8±4.9,P <0.01)。在选择了高灵敏度阈值(SUV max为3.5)以避免假阴性后,以100%的敏感性和86%的特异性(准确性为96%)确定恶性肿瘤。形态学成像的敏感性达到82%,特异性达到86%(准确性为83%)。除1例外,使用SUV最大值为3.5的代谢阈值均可纠正形态学上的假阳性和假阴性决定。此外,通过全身18F-FDG PET / CT检测出4例患者的心外肿瘤表现。结论:18F-FDG PET / CT可以帮助无创性术前确定恶性肿瘤,可能有助于检测恶性心脏肿瘤的转移。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号